Major Changes to Ohio Cannabis Law Will Take Effect Friday
Ohio cannabis law changes represent a significant shift in state-level access impacting patient care continuity and provider liability. Clinicians must understand evolving legal contexts affecting treatment and documentation. These changes require…
Ashland Board Takes No Action on Cannabis Club License
The cannabis social consumption venues regulation directly affects patient access and consumption behaviors. Ashland's board took no action on a cannabis club business license, reflecting regulatory uncertainty. These decisions influence how medical…
CCB Deputy Director Miles Named Acting Executive Director
Cannabis regulatory oversight continuity is critical as Nevada appoints Deputy Director Miles as Acting Executive Director. This leadership change supports stable medical cannabis program operations. Patients and clinicians can expect consistent…
President’s Update: Scope of Practice, Medicinal Cannabis, Ahpra News and More
This update covers medicinal cannabis prescribing Australia and recent regulatory changes impacting clinical practice. Ahpra news and scope of practice revisions are central to these developments. Clinicians should monitor these updates to optimize…
Efforts to Expand Employer Rights Against Medical Marijuana Users
Employment protections medical cannabis users face significant challenges due to conflicting state and federal laws. These protections directly impact patient access and adherence to prescribed cannabis treatments. Clinicians must counsel patients on…
Mississippi Lawmakers Approve Changes to Medical Cannabis Program – WAPT
Mississippi medical cannabis program modifications affect patient access and treatment options in a traditionally restrictive state. These changes influence qualifying conditions and physician recommendations. Monitoring these modifications is essential…
Study Highlights Misleading Labels on Delta-8 Products | Cannabis Sciences – Labroots
Recent research reveals significant delta-8 product labeling inaccuracies that affect patient safety and dosing reliability. These misleading labels complicate clinical counseling and risk assessment. Clinicians should prioritize products with…
Weed is Actually ‘Rarely Justified’ to Treat Anxiety or Depression, Says Major Scientific Review
A major scientific review found cannabis anxiety use evidence insufficient to justify its treatment for anxiety or depression. The review highlights potential harms and lack of efficacy. Clinicians should prioritize evidence-based therapies over cannabis…
Clinical Experience and Student Support for Medical Cannabis Use: A Secondary Analysis
Clinical experience medical cannabis plays a crucial role in shaping student support for therapeutic cannabis use. This secondary analysis reveals that hands-on clinical exposure improves healthcare provider attitudes. Understanding this relationship…
House Approves Senate Changes to Mississippi Medical Cannabis Program
Mississippi medical cannabis program changes have been approved by the House to concur with Senate modifications. These changes affect patient access, qualifying conditions, and regulatory standards. Patients and clinicians should stay informed about…